<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551809</url>
  </required_header>
  <id_info>
    <org_study_id>V203-AD</org_study_id>
    <nct_id>NCT02551809</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Neuroscience Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Neuroscience Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase IIa study is to determine whether the AD Immunotherapeutic Vaccine
      (UB-311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and
      immunogenic in mild AD patients. In addition, the efficacy profiles will be evaluated as the
      secondary endpoint.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability and safety profile of UB-311 assessed via recording of all Adverse Events.</measure>
    <time_frame>78 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of UB-311 measured by change from baseline in anti-Aβ antibody level</measure>
    <time_frame>78 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cognitive: Alzheimer´s Disease Assessment Scale- Cognitive (ADAS-Cog)</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in function: Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cognition: Mini-Mental State Examination (MMSE)</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in global assessment: Clinical Dementia Rating-Sum of Boxes (CDR-SB)</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in behavioral assessment: Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of amyloid burden from baseline in 18F-AV-45 PET imaging in selected brain areas</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>3 priming doses followed by 4 boosters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 7 doses of UB-311.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 priming doses followed by 2 boosters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 5 doses of UB-311 and 2 doses of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 7 doses of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-311</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>3 priming doses followed by 4 boosters</arm_group_label>
    <arm_group_label>3 priming doses followed by 2 boosters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>3 priming doses followed by 2 boosters</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of mild Alzheimer's Disease

          -  Mini-Mental State Examination (MMSE) scores between 20 and 26 (inclusive)

          -  Clinical dementia rating (CDR) scores of 0.5 or 1

          -  Other inclusion criteria apply

        Exclusion Criteria:

          -  Clinically significant neurological disease other than Alzheimer's disease

          -  Major psychiatric disorder

          -  Severe systemic disease

          -  Serious adverse reactions to any vaccine

          -  Other exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital (KS-CGMH)</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital (NTUH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital (TVGH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital (LK-CGMH)</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17287052?dopt=Abstract</url>
    <description>Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.</description>
  </link>
  <link>
    <url>http://www.trci.alzdem.com/article/S2352-8737(17)30022-7/abstract</url>
    <description>UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

